Absci Corp., a Vancouver company behind a multi-faceted drug development platform, went public on Thursday. It’s another sign of snowballing interest in new approaches to drug development – a traditionally risky business. Absci focuses on speeding drug development in the preclinical stages. The company has developed and acquired a handful of tools that can predict […]...